Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cardio Diagnostics Holdings's Enterprise Value for the quarter that ended in Mar. 2026 was $-0.77 Mil.
Cardio Diagnostics Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardio Diagnostics Holdings EV-to-EBIT Related Terms
Cardio Diagnostics Holdings EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cardio Diagnostics Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardio Diagnostics Holdings EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cardio Diagnostics Holdings's EV-to-EBIT falls into.
Cardio Diagnostics Holdings's current Enterprise Value is $-1.89 Mil.
Cardio Diagnostics Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardio Diagnostics Holdings (CDIO) has a EV-to-EBIT of 0.28 as of Jul. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cardio Diagnostics Holdings and its competitors. According to the industry distribution chart, Cardio Diagnostics Holdings ranks #44 out of 384 companies in the Biotechnology industry, placing it in the top 11.5%.
Is Cardio Diagnostics Holdings' EV-to-EBIT too high?
Cardio Diagnostics Holdings' current EV-to-EBIT is 0.28. The Biotechnology industry median EV-to-EBIT is 12.17. Cardio Diagnostics Holdings' value of 0.28 is 97.7% below this industry median. Based on the distribution chart, Cardio Diagnostics Holdings ranks #44 out of 384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cardio Diagnostics Holdings has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cardio Diagnostics Holdings' EV-to-EBIT compare to ERNA and LABT?
According to the Biotechnology industry distribution chart, Cardio Diagnostics Holdings ranks #44 out of 384 companies for EV-to-EBIT. This places Cardio Diagnostics Holdings in the top 12% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 12.17. Cardio Diagnostics Holdings' value of 0.28 is 97.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.17, based on 384 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardio Diagnostics Holdings's current EV-to-EBIT of 0.28 is 97.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cardio Diagnostics Holdings and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardio Diagnostics Holdings's current EV-to-EBIT is 0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardio Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings (CDIO) is currently considered Possible Value Trap. The stock's GF Value™ is $2.77, compared to a current price of $1.57 — trading 43.2% below its estimated fair value. The current EV-to-EBIT is 0.28 and 97.7% below the Biotechnology industry median of 12.17. Cardio Diagnostics Holdings' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Cardio Diagnostics Holdings (CDIO), the current EV-to-EBIT is 0.28 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardio Diagnostics Holdings (CDIO) Overvalued in 2026?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings stock appears to be undervalued.
The current stock price of $1.57 is trading 43.2% below its estimated GF Value™ of $2.77.
GuruFocus considers Cardio Diagnostics Holdings to be Possible Value Trap.
Key valuation signals for CDIO:
EV-to-EBIT: 0.28
GF Value™: $2.77 vs. price of $1.57 (43.2% below fair value)
Industry Position: 97.7% below the Biotechnology median (#44 of 384)
No single metric tells the full story. See the CDIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
49GF Score
Get the complete analysis for CDIO
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDIO has been successfully added to your 
